Download PDF
Horm Metab Res 2010; 42(6): 392-399
DOI: 10.1055/s-0030-1247545
Original Article

© Georg Thieme Verlag KG Stuttgart · New York

Reference Intervals for Aldosterone, Renin, and the Aldosterone-to-Renin Ratio in the Population-based Study of Health in Pomerania (SHIP-1)

A. Hannemann1 , N. Friedrich1 , J. Lüdemann1 , H. Völzke2 , R. Rettig3 , J. Peters3 , M. Reincke4 , A. Döring5 , M. Nauck1 , H. Wallaschofski1
  • 1Institut für Klinische Chemie und Laboratoriumsmedizin, Ernst-Moritz-Arndt Universität Greifswald, Greifswald, Germany
  • 2Institut für Community Medicine, Ernst-Moritz-Arndt Universität Greifswald, Greifswald, Germany
  • 3Institut für Physiologie, Ernst-Moritz-Arndt Universität Greifswald, Greifswald, Germany
  • 4Medizinische Klinik, Campus Innenstadt, Ludwig-Maximilians-Universität München, München, Germany
  • 5Institut für Epidemiologie, Helmholtz Zentrum München, München, Germany
Further Information

Publication History

received 30.09.2009

accepted 13.01.2010

Publication Date:
15 February 2010 (online)

Also available at
    Permissions and Reprints

Abstract

The renin-angiotensin-aldosterone system plays a key role in the regulation of human blood pressure. The aldosterone-to-renin ratio (ARR) is widely accepted for screening the primary hyperaldosteronism (PAL). Various cutoffs for positive PAL screening have been defined in patient cohorts from endocrinological referral centers and primary care. However, the distribution of the ARR in the general population is largely unknown. We aim to provide reference ranges for plasma aldosterone concentration (PAC), plasma renin concentration (PRC), and the ARR for the general population of north-east Germany. A cohort of 3 300 subjects participated in the first follow-up of the longitudinal, population-based Study of Health in Pomerania (SHIP). PAC and PRC were measured by radioimmunometric procedures. The reference interval was defined as the central 95% range between the 2.5th and 97.5th percentiles. A reference population comprising 1 347 healthy subjects was selected. Sex and age-specific (25–54 and 55–74 years) reference ranges are presented. The upper reference limit for the ARR was 14.2 and 20.3 in younger, and 22.4 and 25.5 in older men and women, respectively. Time of blood sampling had no influence on the ARR, while beta blockers, and agents acting on the renin-angiotensin system were associated with higher and lower ARR, respectively. Our upper reference limit for the ARR is clearly lower than previously reported values from studies of hypertensive patients in primary care or hypertension referral centers. We confirm that PAC and PRC are associated with various factors, including sex, age, intake of estrogen, and various antihypertensive medications.

Key words

primary aldosteronism - active renin concentration - plasma aldosterone concentration - endocrine hypertension

References

  • 1 Crowley SD, Gurley SB, Coffman TM. AT(1) receptors and control of blood pressure: the kidney and more.  Trends Cardiovasc Med. 2007;  17 30-34
    Google Scholar
  • 2 Beuschlein F. Renin-angiotensin-aldosterone-system (RAAS) und hypertonie.  Thieme-Refresher Innere Medizin. 2008;  R1-R14
    Google Scholar
  • 3 Fardella CE, Mosso L, Gomez-Sanchez C, Cortes P, Soto J, Gomez L, Pinto M, Huete A, Oestreicher E, Foradori A, Montero J. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology.  J Clin Endocrinol Metab. 2000;  85 1863-1867
    Google Scholar
  • 4 Weidmann P. Hyporeninemic hypoaldosteronism and the differential diagnosis of hyperkalemia.  Schweiz Med Wochenschr. 1982;  112 1764-1774
    Google Scholar
  • 5 Torpy DJ, Stratakis CA, Chrousos GP. Hyper- and hypoaldosteronism.  Vitam Horm. 1999;  57 177-216
    Google Scholar
  • 6 Connell JM, MacKenzie SM, Freel EM, Fraser R, Davies E. A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function.  Endocr Rev. 2008;  29 133-154
    Google Scholar
  • 7 Brown NJ. Aldosterone and end-organ damage.  Curr Opin Nephrol Hypertens. 2005;  14 235-241
    Google Scholar
  • 8 Krug AW, Ehrhart-Bornstein M. Adrenocortical dysfunction in obesity and the metabolic syndrome.  Horm Metab Res. 2008;  40 515-517
    Google Scholar
  • 9 Young WF. Primary aldosteronism: renaissance of a syndrome.  Clin Endocrinol (Oxf). 2007;  66 607-618
    Google Scholar
  • 10 Stewart PM. Mineralocorticoid hypertension.  Lancet. 1999;  353 1341-1347
    Google Scholar
  • 11 Stowasser M, Gordon RD, Rutherford JC, Nikwan NZ, Daunt N, Slater GJ. Diagnosis and management of primary aldosteronism.  J Renin Angiotensin Aldosterone Syst. 2001;  2 156-169
    Google Scholar
  • 12 Douma S, Petidis K, Doumas M, Papaefthimiou P, Triantafyllou A, Kartali N, Papadopoulos N, Vogiatzis K, Zamboulis C. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study.  Lancet. 2008;  371 1921-1926
    Google Scholar
  • 13 Schirpenbach C, Reincke M. Screening for primary aldosteronism.  Best Pract Res Clin Endocrinol Metab. 2006;  20 369-384
    Google Scholar
  • 14 Young Jr WF. Minireview: primary aldosteronism – changing concepts in diagnosis and treatment.  Endocrinology. 2003;  144 2208-2213
    Google Scholar
  • 15 Born-Frontsberg E, Reincke M, Rump LC, Hahner S, Diederich S, Lorenz R, Allolio B, Seufert J, Schirpenbach C, Beuschlein F, Bidlingmaier M, Endres S, Quinkler M. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry.  J Clin Endocrinol Metab. 2009;  94 1125-1130
    Google Scholar
  • 16 Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism.  J Am Coll Cardiol. 2005;  45 1243-1248
    Google Scholar
  • 17 Tiu SC, Choi CH, Shek CC, Ng YW, Chan FK, Ng CM, Kong AP. The use of aldosterone-renin ratio as a diagnostic test for primary hyperaldosteronism and its test characteristics under different conditions of blood sampling.  J Clin Endocrinol Metab. 2005;  90 72-78
    Google Scholar
  • 18 Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young Jr WF, Montori VM. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline.  J Clin Endocrinol Metab. 2008;  93 3266-3281
    Google Scholar
  • 19 Schirpenbach C, Seiler L, Maser-Gluth C, Rudiger F, Nickel C, Beuschlein F, Reincke M. Confirmatory testing in normokalaemic primary aldosteronism: the value of the saline infusion test and urinary aldosterone metabolites.  Eur J Endocrinol. 2006;  154 865-873
    Google Scholar
  • 20 Jansen PM, Boomsma F, van den Meiracker AH. Aldosterone-to-renin ratio as a screening test for primary aldosteronism – the Dutch ARRAT Study.  Neth J Med. 2008;  66 220-228
    Google Scholar
  • 21 Bauer JH. Age-related changes in the renin-aldosterone system. Physiological effects and clinical implications.  Drugs Aging. 1993;  3 238-245
    Google Scholar
  • 22 John U, Greiner B, Hensel E, Ludemann J, Piek M, Sauer S, Adam C, Born G, Alte D, Greiser E, Haertel U, Hense HW, Haerting J, Willich S, Kessler C. Study of Health In Pomerania (SHIP): a health examination survey in an east German region: objectives and design.  Soz Praventivmed. 2001;  46 186-194
    Google Scholar
  • 23 Tanabe A, Naruse M, Takagi S, Tsuchiya K, Imaki T, Takano K. Variability in the renin/aldosterone profile under random and standardized sampling conditions in primary aldosteronism.  J Clin Endocrinol Metab. 2003;  88 2489-2494
    Google Scholar
  • 24 Hurwitz S, Cohen RJ, Williams GH. Diurnal variation of aldosterone and plasma renin activity: timing relation to melatonin and cortisol and consistency after prolonged bed rest.  J Appl Physiol. 2004;  96 1406-1414
    Google Scholar
  • 25 Brandenberger G, Follenius M, Muzet A, Ehrhart J, Schieber JP. Ultradian oscillations in plasma renin activity: their relationships to meals and sleep stages.  J Clin Endocrinol Metab. 1985;  61 280-284
    Google Scholar
  • 26 White WB. Importance of blood pressure control over a 24-hour period.  J Manag Care Pharm. 2007;  13 34-39
    Google Scholar
  • 27 Gallay BJ, Ahmad S, Xu L, Toivola B, Davidson RC. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio.  Am J Kidney Dis. 2001;  37 699-705
    Google Scholar
  • 28 Seifarth C, Trenkel S, Schobel H, Hahn EG, Hensen J. Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism.  Clin Endocrinol (Oxf). 2002;  57 457-465
    Google Scholar
  • 29 Seiler L, Rump LC, Schulte-Monting J, Slawik M, Borm K, Pavenstadt H, Beuschlein F, Reincke M. Diagnosis of primary aldosteronism: value of different screening parameters and influence of antihypertensive medication.  Eur J Endocrinol. 2004;  150 329-337
    Google Scholar
  • 30 Danser AH, Derkx FH, Schalekamp MA, Hense HW, Riegger GA, Schunkert H. Determinants of interindividual variation of renin and prorenin concentrations: evidence for a sexual dimorphism of (pro)renin levels in humans.  J Hypertens. 1998;  16 853-862
    Google Scholar
  • 31 Fischer M, Baessler A, Schunkert H. Renin angiotensin system and gender differences in the cardiovascular system.  Cardiovasc Res. 2002;  53 672-677
    Google Scholar
  • 32 Newton-Cheh C, Guo CY, Gona P, Larson MG, Benjamin EJ, Wang TJ, Kathiresan S, O’Donnell CJ, Musone SL, Camargo AL, Drake JA, Levy D, Hirschhorn JN, Vasan RS. Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample.  Hypertension. 2007;  49 846-856
    Google Scholar
  • 33 Baas SJ, Endert E, Fliers E, Prummel MF, Wiersinga WM. Establishment of reference values for endocrine tests. III: Primary aldosteronism.  Neth J Med. 2003;  61 37-43
    Google Scholar
  • 34 Perschel FH, Schemer R, Seiler L, Reincke M, Deinum J, Maser-Gluth C, Mechelhoff D, Tauber R, Diederich S. Rapid screening test for primary hyperaldosteronism: ratio of plasma aldosterone to renin concentration determined by fully automated chemiluminescence immunoassays.  Clin Chem. 2004;  50 1650-1655
    Google Scholar
  • 35 Trenkel S, Seifarth C, Schobel H, Hahn EG, Hensen J. Ratio of serum aldosterone to plasma renin concentration in essential hypertension and primary aldosteronism.  Exp Clin Endocrinol Diabetes. 2002;  110 80-85
    Google Scholar
  • 36 Olivieri O, Ciacciarelli A, Signorelli D, Pizzolo F, Guarini P, Pavan C, Corgnati A, Falcone S, Corrocher R, Micchi A, Cressoni C, Blengio G. Aldosterone to Renin ratio in a primary care setting: the Bussolengo study.  J Clin Endocrinol Metab. 2004;  89 4221-4226
    Google Scholar
  • 37 Ferrari P, Shaw SG, Nicod J, Saner E, Nussberger J. Active renin versus plasma renin activity to define aldosterone-to-renin ratio for primary aldosteronism.  J Hypertens. 2004;  22 377-381
    Google Scholar
  • 38 Unger N, Lopez Schmidt I, Pitt C, Walz MK, Philipp T, Mann K, Petersenn S. Comparison of active renin concentration and plasma renin activity for the diagnosis of primary hyperaldosteronism in patients with an adrenal mass.  Eur J Endocrinol. 2004;  150 517-523
    Google Scholar
  • 39 Westerdahl C, Bergenfelz A, Isaksson A, Wihl A, Nerbrand C, Valdemarsson S. High frequency of primary hyperaldosteronism among hypertensive patients from a primary care area in Sweden.  Scand J Prim Health Care. 2006;  24 154-159
    Google Scholar
  • 40 Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.  Hypertension. 2008;  51 1403-1419
    Google Scholar
  • 41 Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr, JL, Jones DW, Materson BJ, Oparil S, Wright Jr JT, Roccella EJ. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.  Hypertension. 2003;  42 1206-1252
    Google Scholar
  • 42 Koch CA, Wofford MR, Ayala AR, Pacak K. Overview of Endocrine Hypertension. In: DeGroot (ed) http://www.endotext.com S. Darthmouth: MDTEXT.COM, INC, version of December 11, 2009
    Google Scholar
  • 43 Willenberg HS, Schinner S, Ansurudeen I. New mechanisms to control aldosterone synthesis.  Horm Metab Res. 2008;  40 435-441
    Google Scholar
  • 44 Vasan RS, Evans JC, Larson MG, Wilson PW, Meigs JB, Rifai N, Benjamin EJ, Levy D. Serum aldosterone and the incidence of hypertension in nonhypertensive persons.  N Engl J Med. 2004;  351 33-41
    Google Scholar

Correspondence

A. Hannemann

Institut für Klinische Chemie und Laboratoriumsmedizin

Ernst Moritz Arndt Universität

Ferdinand-Sauerbruch-Straße

17475 Greifswald

Germany

Phone: +49 3834 86 19657

Fax: +49 3834 86 6684

Email: anke.hannemann@uni-greifswald.de

      >